EGFR and HER2-neu Gene Activation in Ovarian Cancer
Author Information
Author(s): Joanna Vermeij, Erik Teugels, Claire Bourgain, Xiangming Ji, Peter 't Veld, Vanessa Ghislain, Bart Neyns, Jacques De Grève
Primary Institution: Universitair Ziekenhuis, Vrije Universiteit Brussel
Hypothesis
What is the status of the EGFR and HER2-neu genes in ovarian cancer and how might this inform targeted therapies?
Conclusion
Genomic alteration of the HER2-neu and EGFR genes is frequent in ovarian cancer, suggesting that targeted therapies should be investigated in this patient subset.
Supporting Evidence
- EGFR was expressed in 59% of cases, with 38% showing high staining intensity.
- HER2-neu expression was found in 35% of cases, with 18% showing high staining intensity.
- No mutations were found in the tyrosine kinase domains of EGFR and HER2-neu.
Takeaway
This study looked at two important genes in ovarian cancer to see if they could help doctors choose better treatments for patients.
Methodology
The study analyzed tumor samples for mutation status, gene copy number, and protein expression using various techniques including immunohistochemistry and FISH.
Potential Biases
Potential bias due to the selection of archived samples and the retrospective nature of the study.
Limitations
The study was retrospective and based on archived samples, which may not represent current clinical practices.
Participant Demographics
All participants were of Caucasian origin.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website